texas oncology more breakthroughs. more victories

Mantle Cell Lymphoma Previously Treated With BTK Inhibitor May Respond to a Newer BTK Inhibitor

Publication: The ASCO Post

The next-generation inhibitor of Bruton’s tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. M. Yair Levy, M.D., a hematologist and medical oncologist at Texas Oncology–Baylor Charles A. Sammons Cancer Center, explains that the results create more options for patients with relapsed or refractory mantle cell lymphoma.

Read the full story at The ASCO Post.

Related Physicians